Metraipolis › archive › dc_3d8a0a6ba2cd

Real-World Indirect Treatment Comparison of Terlipressin vs Midodrine Plus Octreotide in Hepatorenal Syndrome-Acute Kidney Injury — Europe PMC PMID:41472624

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41472624
DOI
10.14309/ctg.0000000000000951
License (as archived)
solo-consultazione
Archived
2026-11-06T09:13:14.256Z
SHA-256 of the archived text
05c4cc89415054fca25cf6c0278fb52029f1c72220bf197a68cb31fcac4c7a60
Stable URL of this page
https://metraipolis.com/documento/dc_3d8a0a6ba2cd

How to cite

Real-World Indirect Treatment Comparison of Terlipressin vs Midodrine Plus Octreotide in Hepatorenal Syndrome-Acute Kidney Injury — Europe PMC PMID:41472624 — Europe PMC (en), https://europepmc.org/article/MED/41472624 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3d8a0a6ba2cd (Metraipolis archive dc_3d8a0a6ba2cd, sha256 05c4cc89415054fca25cf6c0278fb52029f1c72220bf197a68cb31fcac4c7a60)
BibTeX
@misc{dc3d8a0a6ba2cd,
  title = {Real-World Indirect Treatment Comparison of Terlipressin vs Midodrine Plus Octreotide in Hepatorenal Syndrome-Acute Kidney Injury — Europe PMC PMID:41472624},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41472624},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3d8a0a6ba2cd; sha256 05c4cc89415054fca25cf6c0278fb52029f1c72220bf197a68cb31fcac4c7a60},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41472624. Agents can read the archived copy with the MCP tool read_document.